Abstract
In the past two decades, immense advances have been achieved in the engineering, production and purifying of recombinant proteins. These proteins are being widely utilized in many fields of biology, biotechnology and medicine, including diagnostic and therapeutic applications. These applications often require the modification or conjugation of these proteins with other molecules. Researchers are spending many efforts to develop and improve the methods of protein modifications. A main challenge they face is derivatizing proteins without affecting their structure and biological function.
The conjugation methods available today include random and specific chemical modifications on endogenous amino acids or carbohydrate of the protein of interest. Other methods utilize self-labeling tags as fusion partners to the original protein enabling site-specific conjugation. SNAP-tag is one of the most promising self-labeling tags, which reacts specifically, rapidly and covalently with benzylguanine (BG) derivatives.
SNAP-tag fusion proteins have been successfully used for imaging living cells. Recently, several studies have utilized the SNAP technology for generating antibody-based diagnostic and therapeutic tools. We here review these approaches and their possible impact on improving cancer targeting.
Current Pharmaceutical Design
Title:SNAP-Tag Technology: A Powerful Tool for Site Specific Conjugation of Therapeutic and Imaging Agents
Volume: 19 Issue: 30
Author(s): Ahmad Fawzi Hussain, Manal Amoury and Stefan Barth
Affiliation:
Abstract: In the past two decades, immense advances have been achieved in the engineering, production and purifying of recombinant proteins. These proteins are being widely utilized in many fields of biology, biotechnology and medicine, including diagnostic and therapeutic applications. These applications often require the modification or conjugation of these proteins with other molecules. Researchers are spending many efforts to develop and improve the methods of protein modifications. A main challenge they face is derivatizing proteins without affecting their structure and biological function.
The conjugation methods available today include random and specific chemical modifications on endogenous amino acids or carbohydrate of the protein of interest. Other methods utilize self-labeling tags as fusion partners to the original protein enabling site-specific conjugation. SNAP-tag is one of the most promising self-labeling tags, which reacts specifically, rapidly and covalently with benzylguanine (BG) derivatives.
SNAP-tag fusion proteins have been successfully used for imaging living cells. Recently, several studies have utilized the SNAP technology for generating antibody-based diagnostic and therapeutic tools. We here review these approaches and their possible impact on improving cancer targeting.
Export Options
About this article
Cite this article as:
Hussain Fawzi Ahmad, Amoury Manal and Barth Stefan, SNAP-Tag Technology: A Powerful Tool for Site Specific Conjugation of Therapeutic and Imaging Agents, Current Pharmaceutical Design 2013; 19 (30) . https://dx.doi.org/10.2174/1381612811319300014
DOI https://dx.doi.org/10.2174/1381612811319300014 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
1,5-Diaryl-3-oxo-1,4-pentadienes: A Case for Antineoplastics with Multiple Targets
Current Medicinal Chemistry Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Patent Selections
Recent Patents on Drug Delivery & Formulation How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Current Proteomics Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Impaired Expression and Function of Cancer-Related Enzymes by Anthocyans: An Update
Current Enzyme Inhibition TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Boronated Compounds for Imaging Guided BNCT Applications
Anti-Cancer Agents in Medicinal Chemistry Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway
Current Cancer Drug Targets EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Patent Selections:
Recent Patents on Medical Imaging Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 2. Structural Analogues and Derivatives
Current Drug Targets Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors
Current Drug Targets